

Notice to 340B Covered Entities Regarding Panzyga Immune Globulin Intravenous  
(Human) - ifas 10% Liquid Preparation

This notice provides information for 340B covered entities about how to acquire Panzyga Immune Globulin Intravenous (Human) - ifas 10% Liquid Preparation (Panzyga) at prices no greater than the 340B ceiling prices. Panzyga is indicated for primary humoral immunodeficiency in patients two years of age and older, and chronic immune thrombocytopenia in adults. Pfizer, Inc (Pfizer) markets Panzyga under the following NDCs:

<b>Description</b>	<b>Carton NDC</b>
PANZYGA IVIG 1000mg/10mL SSOL 1x1 VL	00069-1011-02
PANZYGA IVIG 2500mg/25mL SSOL 1x1 VL	00069-1109-02
PANZYGA IVIG 5000mg/50mL SSOL 1x1 VL	00069-1224-02
PANZYGA IVIG 10000mg/100mL SSOL 1x1 VL	00069-1312-02
PANZYGA IVIG 20000mg/200mL SSOL 1x1 VL	00069-1415-02
PANZYGA IVIG 30000mg/300mL SSOL 1x1 VL	00069-1558-02

As of the launch of Panzyga in November 2018, Panzyga has been marketed under the Octapharma labeler code (69892). Panzyga now is being transitioned to Pfizer NDCs, as reflected in the table above, however, there will be a period of time in which both Pfizer-labeled Panzyga and Octapharma-labeled Panzyga will be in the distribution channel. Below is the listing of the Octapharma-labeled Panzyga NDCs, which are in the process of being phased out:

<b>Description</b>	<b>Carton NDC</b>
PANZYGA IVIG 1000mg/10mL SSOL 1x1 VL	68982-0820-01
PANZYGA IVIG 2500mg/25mL SSOL 1x1 VL	68982-0820-02
PANZYGA IVIG 5000mg/50mL SSOL 1x1 VL	68982-0820-03
PANZYGA IVIG 10000mg/100mL SSOL 1x1 VL	68982-0820-04
PANZYGA IVIG 20000mg/200mL SSOL 1x1 VL	68982-0820-05
PANZYGA IVIG 30000mg/300mL SSOL 1x1 VL	68982-0820-06

Currently, the supply of Panzyga is insufficient to meet the demand. Accordingly, Pfizer relies on a defined distribution network to distribute Panzyga. The network consists of specialty distributors, who will sell through to select home infusion providers and specialty pharmacies. In addition, due to the limited supply of Panzyga, Pfizer has implemented an allocation procedure. Under the procedure, Pfizer has designated a specified proportion of Panzyga (based on previous Ig purchase volume of 340B covered entities) for purchase by 340B covered entities. Covered entities wishing to purchase Panzyga may contact ASD Healthcare using the information below:

ASD Healthcare  
3101 Gaylord Parkway  
Frisco, TX 75035  
800-746-6273  
[www.asdhealthcare.com](http://www.asdhealthcare.com)

Alternatively, if a 340B covered entity prefers to order from another specialty distributor, it can do so. In such cases, the 340B covered entity may order from its preferred distributor, and ASD will ship Panzyga directly to the covered entity and bill the distributor of the covered entity's choice. The covered entity then will be billed by its preferred distributor.

Pfizer takes its obligations under the 340B program seriously and developed its network in an evenhanded manner that treats all purchasers equally, and does not discriminate against 340B covered entities. As such, this defined distribution network and allocation procedure complies fully with the relevant 340B program guidance. If you have any questions regarding the distribution of Panzyga, or experience any difficulty obtaining any of these products at prices no greater than the 340B ceiling price for your eligible patients, please contact Aaron R. Lillybridge at 224-212-3352.